查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472015

耳部感染治療市場規模 - 按感染類型、病原體、治療、給藥途徑、最終用途 - 全球預測，2024 年 - 2032 年

Ear Infection Treatment Market Size - By Infection Type, Pathogen, Treatment, Route of Administration, End-use - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於耳部感染（尤其是兒童感染）的流行，預計 2024 年至 2032 年耳部感染治療市場複合年成長率將超過 4.9%。根據世界衛生組織的報告，預計到 2050 年，大約 25 億人將遭受不同程度的聽力障礙，其中至少 7 億人需要聽力復健。醫療技術和診斷技術的強勁進步提高了耳部感染診斷的準確性，有助於及時、適當的治療。此外，醫療保健專業人員和患者對未經治療的耳部感染相關潛在併發症的認知不斷提高，這將推動對及時有效的治療解決方案的需求。

此外，不斷增加的醫療保健支出和不斷增加的容易出現耳部併發症的老年人口已經為有利的報銷政策讓路。擴大採用微創外科手術來治療慢性耳部感染及相關疾病，以及主要參與者的策略性舉措（例如產品發布、合作和收購）將刺激市場成長。

耳部感染治療產業分為感染類型、病原體、治療、給藥途徑、最終用途和地區。

從給藥途徑來看，到2032 年，耳科領域的市場佔有率預計將實現5% 的複合年成長率，因為與口服藥物相比，直接向受影響的耳朵提供標靶和局部治療以提高療效並減少全身副作用的需求不斷增加。包括抗生素、類固醇和抗真菌藥物在內的多種耳用製劑的出現，有助於應對各種類型和嚴重程度的耳部感染，為醫療保健專業人員提供靈活的治療選擇。此外，與耳部治療相關的給藥的便利性和易用性有助於提高患者的依從性，同時確保及時有效地治療耳部感染。

根據最終用途，耳鼻喉科診所的耳部感染治療市場預計在 2024 年和 2032 年期間複合年成長率為 5.1%。 ，並為患者提供專家護理和量身定做的治療方案。耳部感染和相關疾病的日益普及也推動了對耳鼻喉診所提供的專業醫療保健服務的需求。

歐洲耳部感染治療產業預計將獲得動力，到 2032 年將以 4.5% 的複合年成長率成長，這要歸功於先進的醫療基礎設施和診斷技術的可用性，促進準確的診斷和及時的干涉。此外，擴大採用微創手術技術來治療慢性耳部感染及相關併發症，將推動歐洲市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 耳部感染盛行率增加
      • 醫療技術不斷進步
      • 不斷增加的政府措施和政策
    • 產業陷阱與挑戰
      • 增加抗生素抗藥性
      • 與手術相關的高費用
  • 成長潛力分析
  • 技術景觀
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按感染類型，2018 年 - 2032 年

  • 主要趨勢
  • 中耳
  • 外耳
  • 內耳

第 6 章：市場估計與預測：按病原體分類，2018 - 2032 年

  • 主要趨勢
  • 細菌
  • 病毒
  • 菌

第 7 章：市場估計與預測：按處理方式，2018 - 2032

  • 主要趨勢
  • 手術
  • 藥物
    • 抗生素
    • 止痛藥
    • 抗病毒劑

第 8 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

  • 主要趨勢
  • 專題
  • 口服
  • 奧迪克
  • 其他給藥途徑

第 9 章：市場估計與預測：按最終用途，2018 - 2032 年

  • 主要趨勢
  • 醫院
  • 耳鼻喉科診所
  • 家庭護理設置
  • 其他最終用戶

第 10 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 11 章：公司簡介

  • Candela Healthcare Private Limited
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • FDC Limited
  • Glenmark Pharmaceuticals Limited
  • Leeford Healthcare Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Torque Pharmaceuticals Pvt. Ltd.
  • Torrent Pharmaceuticals
  • WraSer Pharmaceuticals
簡介目錄
Product Code: 8181

Ear infection treatment market is predicted to witness over 4.9% CAGR from 2024 to 2032, driven by the prevalence of ear infections, particularly among children. As per a WHO report, it is estimated that by 2050, approximately 2.5 billion individuals will experience varying levels of hearing impairment, with at least 700 million necessitating hearing rehabilitation. Robust advancements in medical technology and diagnostic techniques have improved the accuracy of ear infection diagnosis for facilitating timely and appropriate treatment. Moreover, the growing awareness among healthcare professionals and patients regarding the potential complications associated with untreated ear infections will drive the demand for prompt and effective treatment solutions.

Moreover, increasing healthcare expenditure and the growing geriatric population prone to ear-related complications have made way for favorable reimbursement policies. The rising adoption of minimally invasive surgical procedures for the treatment of chronic ear infections and associated conditions along with strategic initiatives by key players, such as product launches, collaborations, and acquisitions will stimulate the market growth.

The ear infection treatment industry is divided into infection type, pathogen, treatment, route of administration, end-use, and region.

By route of administration, the market share from the otic segment is set to witness 5% CAGR up to 2032, due to rising need to offer targeted and localized therapy directly to the affected ear for enhanced efficacy and reduced systemic side effects compared to oral medications. The availability of a wide range of otic formulations, including antibiotics, steroids, and antifungals, is helping cater to various types and severities of ear infections, providing healthcare professionals with flexible treatment options. Moreover, the convenience and ease of administration associated with otic treatments is contributing to improved patient compliance while ensuring timely and effective management of ear infections.

Based on end use, the ear infection treatment market from the ENT clinics segment is anticipated to observe a 5.1% CAGR during 2024 and 2032. These clinics serve as specialized centers for diagnosing and treating various ear, nose, and throat conditions, including ear infections, and providing patients with access to expert care and tailored treatment options. The increasing prevalence of ear infections and related disorders is also driving the demand for specialized healthcare services offered by ENT clinics.

Europe ear infection treatment industry is anticipated to gain momentum and grow at a 4.5% CAGR through 2032, attributed to the availability of advanced healthcare infrastructure and diagnostic technologies that facilitates accurate diagnosis and timely intervention. Furthermore, the growing adoption of minimally invasive surgical techniques for the treatment of chronic ear infections and related complications will propel the market growth in Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of ear infection
      • 3.2.1.2 Growing advancements in medical technology
      • 3.2.1.3 Rising government initiatives and policies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Increasing antibiotic resistance
      • 3.2.2.2 High cost associated with surgery
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Infection Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Middle ear
  • 5.3 Outer ear
  • 5.4 Inner ear

Chapter 6 Market Estimates and Forecast, By Pathogen, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Bacteria
  • 6.3 Virus
  • 6.4 Fungus

Chapter 7 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Surgery
  • 7.3 Medication
    • 7.3.1 Antibiotics
    • 7.3.2 Analgesics
    • 7.3.3 Antiviral

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Topical
  • 8.3 Oral
  • 8.4 Otic
  • 8.5 Other routes of administration

Chapter 9 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital
  • 9.3 ENT clinics
  • 9.4 Homecare settings
  • 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Candela Healthcare Private Limited
  • 11.2 Cipla Ltd.
  • 11.3 Dr. Reddy's Laboratories
  • 11.4 FDC Limited
  • 11.5 Glenmark Pharmaceuticals Limited
  • 11.6 Leeford Healthcare Ltd.
  • 11.7 Novartis AG
  • 11.8 Pfizer Inc.
  • 11.9 Sanofi SA
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Torque Pharmaceuticals Pvt. Ltd.
  • 11.12 Torrent Pharmaceuticals
  • 11.13 WraSer Pharmaceuticals